Exercise Physiology Data Show Menstrual Cycle Phase Has No Measurable Effect on Vascular or Muscle Outcomes

The team tested endothelial function, arterial stiffness, and resistance-training adaptations at multiple cycle phases in cohorts of naturally cycling women and those using combined oral contraceptives. Absolute changes in flow-mediated dilation stayed within 0.5 percentage points across phases; one-repetition-maximum gains differed by less than 3 percent between groups. These null results were replicated in subsequent studies of substrate metabolism and recovery markers.

The exclusion practice originated in a 1995 paper that reported cycle-related variability, yet later meta-analyses of more than 1,200 women showed effect sizes below 0.2 for most performance variables. This mirrors the earlier cardiology shift after sex-stratified trials revealed different myocardial infarction symptom profiles and outcomes in women versus men.

Because the assumption lacked empirical support, entire domains of exercise prescription for women rest on male-derived data. Current guidelines for hypertension, sarcopenia, and athletic training therefore carry unknown sex-specific error margins.

Next steps require adequately powered, cycle-controlled RCTs that report absolute risk reductions separately by sex and include diverse hormonal-contraceptive regimens to close the evidence gap within five years.